The radiation dose range in which OK-432 would promote the recovery of radiation-impaired erythropoiesis was investigated.
OK-432, a multicytokine inducer8-10> and immuno-potentiating anticancer agent,1-13) prevents the radiation-induced bone marrow death in mice, 14"5) and this ability has led to trials of combination therapy with OK-432 and radiotherapy in human medulloblastoma, pinealoma and pons glioma patients.10) In order to apply OK-432 as a radioprotectant to heavily irradiated human subjects, whether from radiation accidents or radiotherapy, further investigations including toxicological studies are required. x5) Because we hypothesized that the induction of cytokines was associated with the state of erythropoiesis, we sought to determine the erythropoietic potential of OK-432. We have shown in a preliminary report that when irradiated with 378 cGy of X-rays, OK-432 appeared to promote the recovery of erythropoiesis in mice. 17> The aim of this study was to further characterize the erythropoietic properties of OK-432. We investigated the radiation dose range where OK-432 would promote the recovery of radiation impaired erythropoiesis. Experimental data has suggested that the alterations caused by radiation are long-lasting.ls-21) Therefore, the state of erythropoietic activity over long intervals following irradiation in OK-432 treated mice was also examined and compared with that of nonirradiated corresponding control.
II MATERIALS AND METHODS
Male C57BL/6J mice, [8] [9] [10] [11] [12] weeks old at the time of irradiation, were housed five per cage at 23 h 1°C and fed a standard cubed diet and acidified water ad libitum. All groups were matched for age and body weight and each experimental group consisted of eight or more mice. The present study was conducted according to the Guidelines for Animal Welfare and Experimentation issued by the National Institute of Radiological Sciences.
Whole body X-irradiation was delivered to mice with a therapeutic X-ray machine (Shimadzu Seisakusho Co. Ltd., Kyoto), operated at 200 kVp, 20 mA, with a dose rate of 74 cGy per minute as a skin target distance of 60 cm; HVL was 1.2 mmCu. As the mice irradiated with 756 cGy of X-rays all died within 26 days after irradiation whether OK-432 treated or not,17) mice used in the present study were irradiated with a total dose ranging from 94.5 cGy to 662 cGy of X-rays.
OK-432, a lyophilized preparation of attenuated strain Su of Streptococcus haemolyticus manufactured by Chugai Pharmaceutical Co. Ltd., Tokyo, was diluted with saline immediately before use. The cell count of OK-432 was expressed as a Klinische Einheit (KE), i.e., 1 KE was equivalent to 0.1 mg of dried cells. One hour before or 1 h after irradiation, mice were intraperitoneally injected with a single dose of 5 KE of OK-432, the same dosage as that previously used.14"7) An equal volume of saline was injected into control mice.
Erythropoietic activity was examined by measuring the uptake of 59Fe into circulating erythrocytes and erythropoietic tissues22> after intraveous injection of 37 kBq of 59Fe-citrate (Amersham, Japan). Incorporation of 59Fe into heme and nonheme iron fractions of the femoral bone muriaw, spleen and liver was measured by the method of Gresham.23,24) The procedures for the separation of heme and nonheme iron fractions were described in detail previously.17) Radioactivity in the heme and nonheme iron fractions was measured with a NaI scintillation counter and expressed as percentage of the injected activity. This percentage was used as the measure of erythropoietic activity. Changes in erythropoietic activity were measured on the 1st, 3rd, 5th, 7th, 14th and 20th day after irradiation. When irradiated with 567 or 662 cGy of X-rays, the state of erythropoietic activity was also measured on the 60th, 258th or 275th day after irradiation. Healthy young adult and aged mice, matched for age and body weight, were used as corresponding nonirradiated control.
III RESULTS
When irradiated with 94.5 cGy to 567 cGy of X-rays, all mice survived during the experimental period of 20 days post-irradiation whether treated with OK-432 or not (Table 1) . On the 14th day after irradiation with 662 cGy of X-rays, the survival rates (animals surviving/animals used) of 37% (7/19), 47% (9/19) and 42% (8/19), respectively, of OK-432 untreated, OK-432 treated 1 hour before or after irradiation groups were not very different from each other. During the 14-to 20-day period after irradiation with this dosage , all the remaining mice of the untreated group died, whereas several mice were still alive on the 20th day in the OK-432 treated groups (Table 1) .
Serial changes in erythropoietic activity were examined after irradiation with different doses. Although there is a dose-related difference in the timing and extent of the response, the serial changes in erythropoietic activity were observed to follow fairly similar patterns. Changes in 378 cGy irradiated groups were shown in the previous paper17) as a representative model of these serial changes. Because in the present study a much larger dose of 662 cGy was given to mice, the serial changes in the irradiated groups with this dosage are shown as an example in Fig. 1 and 2 . When irradiated with 94.5 to 567 cGy of X-rays, mice without OK-432 treatment showed endogenous erythropoietic recovery within 20 days after irradiation. This recovery began approximately 3 days after irradiation on 94.5 cGy irradiated mice, 5 days after in 189 cGy irradiated mice, 7 days after with 284 or 378 cGy, 14 days after Jwith 473 cGy, and between the 14th and 20th day post-irradiation with 567 cGy. On the other hand, when irradiated with 662 cGy, mice showed no tendency of recovery within 20 days after irradiation. These results indicated that the start of endogenous recovery in OK-432 untreated groups was directly related to the radiation dosage, with successively larger doses causing longer delays until recovery could begin.
Serial changes in splenic weight, 59Fe uptake into the heme fraction of spleen and femoral bone marrow and 59Fe into the nonheme fraction of the liver after irradiation with 662 cGy of X-rays with or without OK-432 treatment are shown in Fig. 1 , as well as the data on unirradiated control. During the first 14 days after irradiation, there were no significant differences in these parameters of the spleen in OK-432 treated groups was observed as compared with untreated groups when irradiated with 284 to 473 cGy. On the other hand, a decrease of 59Fe into the heme iron fraction of femoral bone marrow was observed in the treated groups when irradiated with 94.5 to 284 cGy. The 59Fe incorporation into the nonheme iron fraction of the liver showed no particular tendency with 94.5 to 378 cGy, but when exposed to 473 to 567 cGy, a significant decrease was observed in the treated groups. The uptake of 59Fe into circulating erythrocytes was promoted within 20 days after irradiation when treated with OK-432. This enhancement was observed to some degree when irradiated with 94.5 to 189 cGy, but became even more evident with 284 to 567 cGy. When irradiated with 662 cGy, the group treated with OK-4321 h before irradiation showed a much higher uptake of 59Fe into erythrocytes on the 20th day than the group treated 1 h postirradiation. When irradiated with 94.5 to 567 cGy, however, there was no particular indication that the treatment with OK-432 1 h before irradiation was more effective than that 1 h after.
When irradiated with 662 cGy of X-rays, the survival rate of mice on the 60th day after irradiation was 30 %, 60 % and 60 %, in the untreated, treated 1 h before, and 1 h after irradiation groups, respectively ( Table 2) . On this day, spleen weight in all irradiated groups was less than the corresponding unirradiated control, but a partial increase in 59Fe into the heme iron fraction of femoral bone marrow was observed in OK-432 treated and nontreated groups as compared with the corresponding unirradiated control. 59Fe into erythrocytes was almost the same as the unirradiated corresponding control in all irradiated groups whether treated with OK-432 or not.
When irradiated with 567 cGy of X-rays, the survival rate on the 258th day after irradiation was 10%, 20% and 15%, in the untreated, treated 1 h before, and 1 h after irradiation groups, respectively. When irradiated with 662 cGy, the survival rate on the 275th day was 5%, 20% and 25%, respectively. The weight of the spleen in all irradiated groups was less than the corresponding unirradiated control at 258 days or more after irradiation, and 59Fe into the splenic heme iron fraction in the OK-432 treated groups was also less than the corresponding unirradiated control. In contrast to splenic weight, a significant increase in 59Fe into the heme fraction of femoral bone marrow was observed in the treated groups compared with the corresponding unirradiated control. Finally, 59Fe uptake into erythrocytes in the treated groups was almost the same as the corresponding unirradiated control at 60 days or more after irradiation.
IV DISCUSSION
When humans are exposed to a potentially lethal or sub-lethal dose of radiation, whether by radiotherapy or radiation accident, bone marrow failure due to granulocytopenia and/or thrombocytopenia is a possible consequence. In such cases, infection and bleeding are common and may be fatal.25,26) In the present study, the injection of OK-432 resulted in increased survivals of mice irradiated with 662 cGy of X-rays. Within 20 days after irradiation with 189 to 473 cGy, the weight of the spleen increased in comparison to control. The ability of OK-432 to protect mice from radiation-induced granulocytopenia and thrombocytopenia was considered to be the main reason for the high survival rate and increased splenic weight in the present study.
Erythroid precursor cells are somewhat more sensitive to radiation than those of the granuloid system,2) and erythropoietic impairment following radiation has been demonstrated by as little as 5 rads.28) Therefore, the prognosis for exposed animals depends, in part, on whether decreased erythropoiesis is involved or not. Although the radioprotective effect of OK-432 may be mainly attributed to the prevention of granulocytopenia and thrombocytopenia,4"9) in in vitro studies, OK-432 has been shown to accelerate not only CFU-GEMM, CFU-C and CFU-Meg, but also BFU-e colony formation.29-31) The erythropoietic potential of OK-432 has attracted special interest recently in terms of its use as a radioprotectant in radiation accidents and radiotherapy.10) In this regard, our present study was performed in order to determine the radiation dose range in which OK-432 would be effective in promoting the recovery of radiation impaired erythropoiesis. Whether erythropoietic activity after long intervals post-irradiation with a lethal dose returns to a normal level or not was also examined in OK-432 treated mice.
The kinetics of erythropoietic activity have been studied by 59Fe utilization method, erythroid colony forming assay and erythropoietin assay. The in vitro erythroid colony forming assay, which is a useful tool for evaluating the state of erythropoietic stem cells, may not be an accurate index of erythropoiesis when immatured erythrocytes were destroyed within erythropoietic tissues.32) Changes in the number of erythrocytes and reticulocytes in circulation, as well as hematocrit and hemoglobin values are also used as specific makers for cells of the erythroid series. But most of these makers are not as sensitive to radiation as the 59Fe utilization method, and they usually reflect after lengthy periods following irradiation. In this regard, we limited our measurements to the uptake of 59Fe into circulating erythrocytes, femoral bone marrow, spleen and liver, because these are very simple but highly sensitive, reproducible and direct parameters of erythropoiesis at its later stages,33,34) For estimating erythropoiesis in hematopoietic tissues using 59Fe, the method involving the measurement of 59Fe into heme iron fraction is more reliable than that into total iron fraction.23,24) Therefore, a chemical method for the rapid separation of heme and nonheme iron fractions was employed.
In the present study, treatment with OK-432 resulted in a significant increase in splenic erythropoiesis but not in bone marrow when observed within 20 days after irradiation. This agent was effective even when the application was started 1 h after exposure, as judged by the increase of 59Fe into erythrocytes . The decreased uptake of 59Fe into the nonheme iron fraction of liver in many treated groups also indicated that OK-432 stimulates the recovery of erythropoietic activity after irradiation. All these results confirmed our previous observations.10)
When the dose of X-rays given to mice was increased, the time lag before the start of endogenous recovery was also seen to increase. The serial changes in erythropoietic activity after irradiation in the OK-432 untreated groups (data not shown) were observed to follow similar patterns to those reported by other investigators. 35 ,36) It can be stated with some degree of certainty that the endogenous recovery of X-ray impaired erythropoiesis was promoted by the injection of OK-432. Even when given a lethal dose of 662 cGy, erythropoietic recovery began in OK-432 treated groups between the 14th and 20th day post-irradiation, and on the 20th day the weight and erythropoietic activity of the spleen were much greater than in unirradiated control. It might be possible that erythropoietic stem cells sufficient in number to allow for sustained erythropoietic recovery survive an otherwise lethal dose of irradiation when treated with OK-432 during the period of its greatest potential.l7) Although OK-432 has already been used clinically in Japan for cancer therapy,"2) as far as we know, all these erythropoietic properties of OK-432 have been observed here for the first time.
In the present study, mice were injected with a single dose of 5 KE of OK-432. However, before OK-432 can be used clinically for heavily irradiated humans as a radio-protective agent, investigations including toxicological studies will be required.15) For example, OK-432, a multicytokine inducer and immunopotentiating anticancer agent, is known to induce IL-137) and TNFa 38,39) Recent studies have demonstrated that IL-1 and TNF-a inhibit erythropoiesis in vitro and in vivo.40-43) Therefore, the fact that OK-432 induces IL-1 and TNF-a might limit its clinical use as a therapeutic agent in some circumstances, especially when combined with radiotherapy.l7) When irradiated with small doses of X-rays (94.5 to 284 cGy), 59Fe uptake into heme fraction of femoral bone marrow decreased significantly in some OK-432 treated groups compared with groups without OK-432. It is unknown, however, whether this occurs because of the induction of IL-1 and TNF-a.
On the other hand, splenic erythropoietic recovery after irradiation was stimulated by OK-432, but the reason for this is not yet clear. As previously discussed,i7) the production of factors such as GM-CSF, which is active on immature stem cells may be one of the reasons why OK-432 stimulates erythropoiesis. To what extent erythropoietic properties of OK-432 are responsible for the high survival rate in OK-432 treated mice is not known, nor is the mechanism understood, but the present study has demonstrated that erythropoiesis in irradiated mice recovers more rapidly than corresponding irradiated mice when treated with OK-432.
When considering its clinical application for humans, it is also necessary to determine the minimum dose by which OK-432 can stimulate erythropoietic recovery after irradiation. Studies lymphocytes,48) whether OK-432 will be able to function in a clinical setting in an efficacious manner equal to or better than that of combination cytokine therapy or next-generation compounds is still unknown, but it at least presents an intriguing possibility. Further investigations will be required to ascertain whether the use of OK-432 together with radiotherapy may have the potential of improving the erythropoietic function of cancer patients, and also whether OK-432 could be used as a radioprotective agent after radiation accidents. A subsequent study of the effect of OK-432 on the survival and erythropoiesis of splenectomized and/or irradiated mice is currently in progress.
V CONCLUSION
We have described that OK-432 stimulates the 59Fe uptake into erythrocytes of C57BL/6J male mice when irradiated with 189 to 662 cGy of X-rays. Present results seem to indicate that OK-432 stimulates erythropoiesis in sub-lethally and lethally irradiated mice and allows sustained endogenous erythropoietic recovery. At more than 258 days after irradiation with a lethal dose, the rate of 59Fe uptake into erythrocytes in the OK-432 treated groups was almost the same as in the unirradiated control.
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